Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
0.8900
+0.0531 (6.34%)
At close: May 13, 2025, 4:00 PM
0.8801
-0.0099 (-1.11%)
Pre-market: May 14, 2025, 8:53 AM EDT
Atossa Therapeutics Employees
Atossa Therapeutics had 15 employees as of December 31, 2024. The number of employees increased by 3 or 25.00% compared to the previous year.
Employees
15
Change (1Y)
3
Growth (1Y)
25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,756,267
Market Cap
114.96M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ATOS News
- 55 minutes ago - Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen - PRNewsWire
- 1 day ago - Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate Update - PRNewsWire
- 14 days ago - Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio - GlobeNewsWire
- 15 days ago - Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025 - GlobeNewsWire
- 22 days ago - Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio - GlobeNewsWire
- 4 weeks ago - Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - PRNewsWire
- 7 weeks ago - Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire